您当前的位置：

Cynaroside

(Synonyms: 木犀草苷; Luteolin 7-glucoside; Luteolin 7-O-β-D-glucoside)

目录号: PC13979 纯度: ≥98%

Cynaroside是一个类黄酮的化合物。产品性质

CAS No. :5373-11-5

商品编号	规格	价格	会员价	是否有货	数量
PC13979-20mg	20mg	¥141.25	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称

Cynaroside

中文别名

木犀草苷;木犀草素-7-O-葡萄糖甙;藤黄菌素-7 -O-葡糖苷;木犀草素-7-葡萄糖苷;木樨草素-7-O-葡萄糖甙;木犀草素-7-O-葡萄糖苷;青兰苷;木犀草素7-O-Β-D-吡喃葡萄糖苷;1268798 木犀草苷对照品;卢特噢琳糖苷;木犀草苷 Cynaroside 青兰苷;木犀草苷 Luteoloside;木犀草苷标准品;木犀草苷(标准品);木犀草苷,Cynaroside,植物提取物,标准品,对照品;木犀草苷Cynaroside;木犀草素;木犀素-7-0-葡萄糖苷;木犀草素7-0葡萄糖苷;木犀草素-7-O-β-D-葡萄糖苷;木犀草素-7-O-葡萄糖苷,青兰苷

英文名称

Cynaroside

英文别名

Luteolin-7-glucoside;PETUNIDIN;2-(3,4-dihydroxyphenyl)-7-(beta-d-glucopyranosyloxy)-5-hydroxy-4h-1-benzopyr;4h-1-benzopyran-4-one,2-(3,4-dihydroxyphenyl)-7-(beta-d-glucopyranosyloxy)-5-h;7-glucoluteolin;7-glucosylluteolin;cinaroside;glucoluteolin;luteolin7-monoglucoside;Luteoloside;Cynaroside;Luteolin 7-beta-glucoside;Luteolin 7-glucoside;Luteolin-7-O-glucoside;LUTEOLIN-7-O-GLUCOSIDE(P);LUTEOLIN-7-O-GLUCOSIDE(P) PrintBack;Luteolin-7-O-β-D-glucoside;lCynaroside;Daphneflavonoloside;Flavopurposide;Galuteolin;Luteolin 7-b-glucoside;luteolin 7-O-beta-D-glucoside;Luteolin 7-O-β-D-glucoside;Luteolin-7-O-Beta-D-glucoside;Nephrocizin;Nephrocizine;Luteolin 7-O-D-glucoside;2-(3,4-Dihydroxyphenyl)-5-hydroxy-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one;[ "Cynaroside" ];Luteolin 7-O-glucoside;Luteolin 7-monoglucoside;Luteolin 7-O-glucopyranoside;7-O-beta-D-Glucosyl-5,7,3',4'-tetrahydroxyflavone;MLS002473222;98J6XDS46I;SMR000232358;2-(3,4-Dihydroxyphenyl)-7-(beta-D-glucopyranosyloxy)-5

Cas No.

5373-11-5

分子式

C₂₁H₂₀O₁₁

分子量

448.38

包装储存

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

生物活性

Cynaroside (Luteolin 7-glucoside) is a flavonoid compound that exhibits anti-oxidative capabilities. Cynaroside is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC₅₀ of 32 nM. Cynaroside also is a promising inhibitor for H₂O₂-induced apoptosis, has cytoprotection against oxidative stress-induced cardiovascular diseases. Cynaroside also has antibacterial, antifungal and anticancer activities, antioxidant and anti-inflammatory activities.

性状

Solid

IC50 & Target[1][2]

IC50:32 nM (RNA polymerase inhibitor)

体外研究(In Vitro)

Cynaroside promots macrophage phenotypic transition from pro-inflammatory M1 to anti-inflammatory M2, and mitigates sepsis-associated liver inflammatory damage.
Cynaroside reduces binding of PKM2 to hypoxia-inducible factor-1α (HIF-1α) by abolishing translocation of PKM2 to the nucleus and promoting PKM2 tetramer formation, as well as suppressing phosphorylation of PKM2 at Y105 in vivo and 体外研究.
Cynaroside restores pyruvate kinase activity, inhibits glycolysis-related proteins including PFKFB3, HK2 and HIF-1α, and inhibits glycolysisrelated hyperacetylation of HMGB1 in septic liver.
Cynaroside protects H9c2 cells against H₂O₂-induced apoptosis by decreasing ROS generation and inhibiting caspase activation in both the mitochondrial and death receptor pathways.
Cynaroside maintains mitochondrial function by regulating Bcl-2 protein expression, as well as JNK and P53 expression.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	RAW264.7 cell
Concentration:	5μM, 10μM
Incubation Time:	2 h
Result:	Reduced expression levels of IL-1β, IL-6 and TNF-α and HMGB1, suppressed M1 polarized phenotype in RAW264.7 cells.

Immunofluorescence

Cell Line:	RAW264.7 cell
Concentration:
Incubation Time:	4 h
Result:	Decreased PKM2 nuclear translocation in hepatic macrophages of septic mice.

RT-PCR

Cell Line:	RAW264.7 cell
Concentration:	2.5μM, 5μM, 10μM
Incubation Time:
Result:	Increased increased expression levels of M2 markers Arg-1, IL-10 andCD206.

Cell Viability Assay

Cell Line:	H9c2 cells
Concentration:	25, 50, 100 μg/mL
Incubation Time:	4 h
Result:	Protected H9c2 cells from oxidative stress-induced cell injury.

Apoptosis Analysis

Cell Line:	H9c2 cells
Concentration:	25, 50, 100 μg/mL
Incubation Time:	4 h
Result:	Decreased H₂O₂-induced apoptosis in H9C2 cells.

体内研究(In Vivo)

Cynaroside (i.p.; 5mg/kg) reduces binding of PKM2 to hypoxia-inducible factor-1α (HIF-1α) by abolishing translocation of PKM2 to the nucleus and promoting PKM2 tetramer formation, as well as suppressing phosphorylation of PKM2 at Y105.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice model of sepsis
Dosage:	5mg/kg
Administration:	Cynaroside (i.p.; 5mg/kg)
Result:	Inhibited PKM2 dimer formation in liver of septic mice.

运输条件

Room temperature or refrigerated transportation.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

结构分类

来源

参考文献

[1]. Václav Zima, et al. Unraveling the Anti-Influenza Effect of Flavonoids: Experimental Validation of Luteolin and its Congeners as Potent Influenza Endonuclease Inhibitors. Eur J Med Chem. 22 August 2020, 112754.

[2]. Liuhua Pei, et al. Cynaroside prevents macrophage polarization into pro-inflammatory phenotype and alleviates cecal ligation and puncture-induced liver injury by targeting PKM2/HIF-1α axis. Fitoterapia. 2021 Jul;152:104922. [Information]

[3]. Xiao Sun, et al. Protective effects of cynaroside against H?O?-induced apoptosis in H9c2 cardiomyoblasts. J Cell Biochem. 2011 Aug;112(8):2019-29. [Information]

[4]. Shams Tabrez, et al. Cynaroside inhibits Leishmania donovani UDP-galactopyranose mutase and induces reactive oxygen species to exert antileishmanial response. Biosci Rep. 2021 Jan 29;41(1):BSR20203857. [Information]

溶解度数据

体外研究:

DMSO : 83.33 mg/mL (185.85 mM; Need ultrasonic)

配制储备溶液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.2303 mL	11.1513 mL	22.3025 mL
5 mM	0.4461 mL	2.2303 mL	4.4605 mL
10 mM	0.2230 mL	1.1151 mL	2.2303 mL

产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

建议依照次序添加每种溶剂： 50% PEG300 50% saline
Solubility: 16.67 mg/mL (37.18 mM); Suspended solution; Need ultrasonic
2.

建议依照次序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (4.64 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.64 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH?O 中，得到澄清透明的生理盐水溶液
3.

建议依照次序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (4.64 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.64 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

Cynaroside

相关产品

The molarity calculator equation

The dilution calculator equation